Compare MRK & MS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRK | MS |
|---|---|---|
| Founded | 2000 | 1924 |
| Country | United States | United States |
| Employees | N/A | 83000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | 255.2B |
| IPO Year | 1994 | N/A |
| Metric | MRK | MS |
|---|---|---|
| Price | $115.81 | $166.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 14 |
| Target Price | $124.64 | ★ $177.42 |
| AVG Volume (30 Days) | ★ 7.3M | 6.2M |
| Earning Date | 04-23-2026 | 04-15-2026 |
| Dividend Yield | ★ 2.98% | 2.48% |
| EPS Growth | ★ 8.01 | N/A |
| EPS | ★ 7.28 | N/A |
| Revenue | ★ $65,011,000,000.00 | N/A |
| Revenue This Year | $3.74 | $12.04 |
| Revenue Next Year | $5.47 | $5.39 |
| P/E Ratio | ★ $15.61 | $17.30 |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $75.40 | $94.33 |
| 52 Week High | $125.14 | $192.68 |
| Indicator | MRK | MS |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 51.48 |
| Support Level | $113.82 | $154.82 |
| Resistance Level | $125.14 | $171.77 |
| Average True Range (ATR) | 2.44 | 4.26 |
| MACD | -0.62 | 0.89 |
| Stochastic Oscillator | 37.36 | 80.55 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 82,000 employees as of year-end 2025. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $9.3 trillion in client assets at the end of its most recent fiscal year. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with more than $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.